HEALTH AND SAFETY
» Drug, Devices, and Supplements
» Physician Accountability
» Consumer Product Safety
» Worker Safety
» Health Care Delivery
» Auto and Truck Safety
» Global Access to Medicines
» Infant Formula Marketing
More Information on Celecoxib (Celebrex)
- Letter Concerning Pfizer's Television Advertisement for Celebrex, April 9, 2007
- Statement: Valdecoxib (Bextra) ban a good step, but FDA Should pull Celecoxib (Celebrex) too, April 7, 2005
- Letter in the New York Times on Cox-2 Painkillers: Painkillers and Terrorism, February 19, 2005
- Testimony on the Dangers of Cox-2 Drugs, February 17, 2005
- Petition to Remove the COX-2 Inhibitors Celecoxib (Celebrex) and Valdecoxib (Bextra) from the Market, January 24, 2005
- Letter Revealing Heart Dangers in an Unpublished Clinical Trial of Celecoxib (Celebrex), January 31, 2005
- USA Today Editorial: Take Drugs off the Market, December 27, 2004
- Statement on FDA's Announcement About Use of Celecoxib (Celebrex) and Valdecoxib (Bextra), December 23, 2004
- Letter on Ethical Concerns with the “Alzheimer’s Disease Anti-Inflammatory Prevention Trial” (ADAPT), September 4, 2002
- Testimony on Celecoxib (Celebrex) and Rofecoxib (Vioxx), February 7-8, 2001
- Statement on Celecoxib (Celebrex), December 1, 1998